News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Capricor Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Drug Development
SoCal’s Capricor Places Voluntary Hold on DMD Drug Following Allergic Reaction
Capricor Therapeutics has placed a voluntary hold on its Phase II clinical trial for a Duchene Muscular Dystrophy treatment on hold after a patient experienced a severe allergic reaction during dosing.
December 26, 2018
·
3 min read
·
Alex Keown
Business
Capricor Falls as Johnson & Johnson Bails on Stem Cell Heart Med
July 7, 2017
·
3 min read
Drug Development
SoCal’s Capricor to Reduce Workforce and Shift Focus After Discouraging Trial Results
May 12, 2017
·
2 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
·
13 min read
Press Releases
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
May 4, 2026
·
4 min read
Press Releases
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting
April 23, 2026
·
6 min read
Press Releases
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 13, 2026
·
14 min read
Press Releases
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
March 13, 2026
·
8 min read
Press Releases
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
March 10, 2026
·
6 min read
Press Releases
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
March 9, 2026
·
4 min read
Press Releases
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference
February 24, 2026
·
7 min read
Press Releases
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy
December 17, 2025
·
4 min read
Press Releases
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
December 5, 2025
·
5 min read
